Showing results (31-40 of 143) with videos related to
Sort By:
Pageof 15
Expert Review of Anticancer Therapy|July 1, 2024
First-in-human clinical trial results with ABBV-184, a first-in-class T-cell receptor/anti-CD3 bispecific protein, in adults with previously treated AML or NSCLCPierre Peterlin, Esma Saada-Bouzid, Mor Moskovitz, et al.Cancer|May 25, 2005
Acute leukemia during pregnancy: a report on 37 patients and a review of the literatureYoucef Chelghoum, Norbert Vey, Emmanuel Raffoux, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2008
Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemiaPatrice Chevallier, Jacques Delaunay, Pascal Turlure, et al.Ejhaem|February 26, 2024
Prognostic value of postinduction medullary myeloid recovery by flow cytometry in acute myeloid leukemiaCéline Row, Nicolas Lechevalier, Jean Philippe Vial, et al.Nature Communications|May 26, 2018
Dual origin of relapses in retinoic-acid resistant acute promyelocytic leukemiaJacqueline Lehmann-Che, Cécile Bally, Eric Letouzé, et al.Clinical Lymphoma, Myeloma & Leukemia|September 22, 2020
Antifungal Stewardship in Hematology: Reflection of a Multidisciplinary Group of ExpertsMauricette Michallet, Mohamad Sobh, Gilbert Deray, et al.Oncotarget|November 8, 2017
Azacitidine or intensive chemotherapy for older patients with secondary or therapy-related acute myeloid leukemiaPierre-Yves Dumas, Sarah Bertoli, Emilie Bérard, et al.British Journal of Haematology|December 19, 2024
Olutasidenib demonstrates significant clinical activity in mutated IDH1 acute myeloid leukaemia arising from a prior myeloproliferative neoplasmStéphane De Botton, Christian Récher, Jorge Cortes, et al.Blood Advances|October 27, 2020
Horizontal meta-analysis identifies common deregulated genes across AML subgroups providing a robust prognostic signatureAli Nehme, Hassan Dakik, Frédéric Picou, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2009
Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemiaGary J Schiller, Susan M O'Brien, Arnaud Pigneux, et al.Pageof 15